The researchers reported that administering the peptide to mice reduced CGRP-induced plasma protein extravasation (PPE), indicating the antagonistic effects of the peptide in vivo
Still, Pfizer has decided to discontinue danuglipron after a review of the totality of information, including all clinical data generated to date and recent input from regulators. With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog PF-07976016, which is currently in Phase II development
body composition also plays a role
This suggests that for many people, 10 mg represents the point of diminishing returns, where side effects increase more than benefits
It also marks this strategy as having high individual variability, tying the outcome to a person's baseline gut microbiota rather than to the fiber amount alone
This rural track expansion will ultimately grow to a complement of four OB/GYN residents training on-site at Colquitt Regional at one time